Literature DB >> 30001835

Inter-pathologist and pathology report agreement for ovarian tumor characteristics in the Nurses' Health Studies.

Mollie E Barnard1, Alexander Pyden2, Megan S Rice3, Miguel Linares4, Shelley S Tworoger5, Brooke E Howitt6, Emily E Meserve7, Jonathan L Hecht8.   

Abstract

BACKGROUND: Grade and histotype of ovarian carcinomas are often used as surrogates of molecular subtypes. We examined factors affecting pathologists' reproducibility in two prospective studies.
METHODS: Two pathologists independently reviewed slides from 459 incident ovarian cancers in the Nurses' Health Study (NHS) and NHSII. We described agreement on tumor characteristics using percent agreement and Cohen's standard kappa (κ) coefficients. We used logistic regression, with disagreement as the outcome, to evaluate the contribution of case and tumor characteristics to agreement.
RESULTS: Inter-rater agreement was 95% (κ = 0.81) for carcinoma versus borderline, 89% (κ = 0.58) for grade and 85% (κ = 0.71) for histotype. Inter-rater grading disagreement was higher for non-serous histotypes (OR = 4.66, 95% CI 2.09-10.36) and lower for cancers with bizarre atypia (OR = 0.13, 95% CI 0.04-0.38). Agreement with original pathology reports was 94% (κ = 0.73) for carcinoma versus borderline, 78% (κ = 0.60) for histotype, and 79% (κ = 0.24) for grade. Grading disagreement was significantly lower for tumors with 'solid, pseudoendometrioid or transitional' (SET) architecture (OR = 0.08, 95%CI 0.01-0.84). Date of original diagnosis, hospital type, number of slides available for review, tumor stage, and slide quality were not related to agreement.
CONCLUSION: Overall, inter-rater agreement for tumor type and grade for archival tissue specimens was good. Agreement between the consensus review and original pathology reports was lower. Factors contributing to grading disagreement included non-serous histotype, absence of bizarre atypia, and absence of SET architecture.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Agreement; Grade; Histotype; Ovarian cancer

Mesh:

Year:  2018        PMID: 30001835      PMCID: PMC6102072          DOI: 10.1016/j.ygyno.2018.07.003

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  19 in total

1.  Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium.

Authors:  Martin Köbel; Steve E Kalloger; Sandra Lee; Máire A Duggan; Linda E Kelemen; Leah Prentice; Kimberly R Kalli; Brooke L Fridley; Daniel W Visscher; Gary L Keeney; Robert A Vierkant; Julie M Cunningham; Christine Chow; Roberta B Ness; Kirsten Moysich; Robert Edwards; Francesmary Modugno; Clareann Bunker; Eva L Wozniak; Elizabeth Benjamin; Simon A Gayther; Aleksandra Gentry-Maharaj; Usha Menon; C Blake Gilks; David G Huntsman; Susan J Ramus; Ellen L Goode
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-07-23       Impact factor: 4.254

2.  Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma.

Authors:  Brooke E Howitt; Suchanan Hanamornroongruang; Douglas I Lin; James E Conner; Stephanie Schulte; Neil Horowitz; Christopher P Crum; Emily E Meserve
Journal:  Am J Surg Pathol       Date:  2015-03       Impact factor: 6.394

3.  Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Robert J Morgan; Deborah K Armstrong; Ronald D Alvarez; Jamie N Bakkum-Gamez; Kian Behbakht; Lee-May Chen; Larry Copeland; Marta Ann Crispens; Maria DeRosa; Oliver Dorigo; David M Gershenson; Heidi J Gray; Ardeshir Hakam; Laura J Havrilesky; Carolyn Johnston; Shashikant Lele; Lainie Martin; Ursula A Matulonis; David M O'Malley; Richard T Penson; Sanja Percac-Lima; Mario Pineda; Steven C Plaxe; Matthew A Powell; Elena Ratner; Steven W Remmenga; Peter G Rose; Paul Sabbatini; Joseph T Santoso; Theresa L Werner; Jennifer Burns; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2016-09       Impact factor: 11.908

4.  Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up.

Authors:  Y Shimizu; S Kamoi; S Amada; F Akiyama; S G Silverberg
Journal:  Cancer       Date:  1998-03-01       Impact factor: 6.860

5.  Molecular classification of high grade endometrioid and clear cell ovarian cancer using TCGA gene expression signatures.

Authors:  Boris Winterhoff; Habib Hamidi; Chen Wang; Kimberly R Kalli; Brooke L Fridley; Judy Dering; Hsiao-Wang Chen; William A Cliby; He-Jing Wang; Sean Dowdy; Bobbie S Gostout; Gary L Keeney; Ellen L Goode; Gottfried E Konecny
Journal:  Gynecol Oncol       Date:  2016-04       Impact factor: 5.482

6.  Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma.

Authors:  Robert A Soslow; Guangming Han; Kay J Park; Karuna Garg; Narciso Olvera; David R Spriggs; Noah D Kauff; Douglas A Levine
Journal:  Mod Pathol       Date:  2011-12-23       Impact factor: 7.842

7.  Agreement for tumor grade of ovarian carcinoma: analysis of archival tissues from the surveillance, epidemiology, and end results residual tissue repository.

Authors:  Rayna K Matsuno; Mark E Sherman; Kala Visvanathan; Marc T Goodman; Brenda Y Hernandez; Charles F Lynch; Olga B Ioffe; David Horio; Charles Platz; Sean F Altekruse; Ruth M Pfeiffer; William F Anderson
Journal:  Cancer Causes Control       Date:  2013-02-03       Impact factor: 2.506

8.  Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma.

Authors:  C Blake Gilks; Diana N Ionescu; Steve E Kalloger; Martin Köbel; Julie Irving; Blaise Clarke; Jennifer Santos; Nhu Le; Veronika Moravan; Kenneth Swenerton
Journal:  Hum Pathol       Date:  2008-07-07       Impact factor: 3.466

9.  Integrated genomic analyses of ovarian carcinoma.

Authors: 
Journal:  Nature       Date:  2011-06-29       Impact factor: 49.962

10.  Interrater reliability: the kappa statistic.

Authors:  Mary L McHugh
Journal:  Biochem Med (Zagreb)       Date:  2012       Impact factor: 2.313

View more
  7 in total

1.  Posttraumatic Stress Disorder Is Associated with Increased Risk of Ovarian Cancer: A Prospective and Retrospective Longitudinal Cohort Study.

Authors:  Laura D Kubzansky; Shelley S Tworoger; Andrea L Roberts; Tianyi Huang; Karestan C Koenen; Yongjoo Kim
Journal:  Cancer Res       Date:  2019-09-05       Impact factor: 12.701

Review 2.  Machine Learning of Raman Spectroscopy Data for Classifying Cancers: A Review of the Recent Literature.

Authors:  Nathan Blake; Riana Gaifulina; Lewis D Griffin; Ian M Bell; Geraint M H Thomas
Journal:  Diagnostics (Basel)       Date:  2022-06-17

3.  The association of resistance training with risk of ovarian cancer.

Authors:  Andrea L Buras; Cassandra A Hathaway; Tianyi Wang; Mary K Townsend; Shelley S Tworoger
Journal:  Cancer Med       Date:  2021-03-11       Impact factor: 4.452

4.  Endometrial Tumor Classification by Histomorphology and Biomarkers in the Nurses' Health Study.

Authors:  Jaclyn C Watkins; Michael J Downing; Marta Crous-Bou; Evan L Busch; Maxine Chen; Immaculata De Vivo; George L Mutter
Journal:  J Cancer Epidemiol       Date:  2021-03-12

5.  Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks.

Authors:  Kun-Hsing Yu; Vincent Hu; Feiran Wang; Ursula A Matulonis; George L Mutter; Jeffrey A Golden; Isaac S Kohane
Journal:  BMC Med       Date:  2020-08-18       Impact factor: 8.775

6.  modelBuildR: an R package for model building and feature selection with erroneous classifications.

Authors:  Maximilian Knoll; Jennifer Furkel; Juergen Debus; Amir Abdollahi
Journal:  PeerJ       Date:  2021-02-09       Impact factor: 2.984

7.  Efficacy of an optimal ovarian cancer screening: a best-case scenario study based on real-world data.

Authors:  Lena Steinkasserer; Delmarko Irmgard; Tatjana Weiss; Walter Dirschlmayer; Michael Mossig; Alain G Zeimet; Christian Marth
Journal:  Arch Gynecol Obstet       Date:  2021-06-14       Impact factor: 2.344

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.